
Imunon, Inc. (NASDAQ:IMNN – Free Report) – Equities research analysts at Brookline Capital Markets increased their FY2026 earnings estimates for Imunon in a report issued on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($2.74) per share for the year, up from their prior estimate of ($2.89). The consensus estimate for Imunon’s current full-year earnings is ($2.61) per share. Brookline Capital Markets also issued estimates for Imunon’s Q4 2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.65) EPS and FY2027 earnings at ($2.67) EPS.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Imunon has an average rating of “Hold” and an average target price of $10.00.
Imunon Stock Performance
Shares of IMNN stock opened at $0.58 on Tuesday. Imunon has a 1 year low of $0.49 and a 1 year high of $4.35. The firm has a fifty day moving average price of $1.10 and a 200-day moving average price of $2.06. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.38 and a quick ratio of 1.38.
Imunon (NASDAQ:IMNN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09).
About Imunon
Imunon, Inc. is a clinical-stage biotechnology company developing treatments for cancer. Formerly known as Celsion Corporation, the company adopted the Imunon name in 2022 and is based in Lawrenceville, New Jersey. Its lead candidate, IMNN-001 (formerly GEN-1), is an investigational DNA-based immunotherapy designed to prompt local production of interleukin-12, a protein that can stimulate an immune response against tumors. Imunon is studying the treatment in combination with chemotherapy for newly diagnosed advanced ovarian cancer.
Recommended Stories
- Five stocks we like better than Imunon
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
